Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy
Evaluation of Vaginal and Urinary Microbiome Markers as Predictors of Post-Surgical Urinary Tract Infection
Status: Enrolling
Updated:  12/31/1969
1524
mi
from 91732
Rochester, MN
Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy
Evaluation of Vaginal and Urinary Microbiome Markers as Predictors of Post-Surgical Urinary Tract Infection
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
1569
mi
from 91732
Saint Louis, MO
Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
1569
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  12/31/1969
2303
mi
from 91732
Baltimore, MD
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 12/31/1969
Center for Immunization Research - Johns Hopkins Bloomberg School of Public Health
2303
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  12/31/1969
2305
mi
from 91732
Baltimore, MD
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 12/31/1969
Center for Immunization Research East, Johns Hopkins Bayview Medical Center Campus
2305
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  12/31/1969
2290
mi
from 91732
Laurel, MD
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 12/31/1969
Center for Immunization Research South
2290
mi
from 91732
Laurel, MD
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1777
mi
from 91732
Birmingham, AL
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
356
mi
from 91732
Chandler, AZ
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
356
mi
from 91732
Chandler, AZ
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
365
mi
from 91732
Mesa, AZ
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
365
mi
from 91732
Mesa, AZ
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
353
mi
from 91732
Tempe, AZ
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
353
mi
from 91732
Tempe, AZ
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
427
mi
from 91732
Tucson, AZ
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
21
mi
from 91732
Beverly Hills, CA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
21
mi
from 91732
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
25
mi
from 91732
Fountain Valley, CA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
22
mi
from 91732
Long Beach, CA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
22
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
27
mi
from 91732
Rolling Hills Estates, CA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
27
mi
from 91732
Rolling Hills Estates, CA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
820
mi
from 91732
Centennial, CO
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
820
mi
from 91732
Centennial, CO
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
813
mi
from 91732
Littleton, CO
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
813
mi
from 91732
Littleton, CO
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
824
mi
from 91732
Thornton, CO
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
824
mi
from 91732
Thornton, CO
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
822
mi
from 91732
Westminster, CO
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
822
mi
from 91732
Westminster, CO
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
813
mi
from 91732
Wheat Ridge, CO
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
813
mi
from 91732
Wheat Ridge, CO
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2529
mi
from 91732
Norwich, CT
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2529
mi
from 91732
Norwich, CT
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2122
mi
from 91732
Clearwater, FL
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2122
mi
from 91732
Clearwater, FL
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2233
mi
from 91732
Cocoa Beach, FL
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2233
mi
from 91732
Cocoa Beach, FL
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2235
mi
from 91732
Melbourne, FL
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2235
mi
from 91732
Melbourne, FL
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2220
mi
from 91732
Naples, FL
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2220
mi
from 91732
Naples, FL
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1730
mi
from 91732
Chicago, IL
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1194
mi
from 91732
Arkansas City, KA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1194
mi
from 91732
Arkansas City, KA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1186
mi
from 91732
Wichita, KA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1186
mi
from 91732
Wichita, KA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2300
mi
from 91732
Towson, MD
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2300
mi
from 91732
Towson, MD
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1512
mi
from 91732
Fridley, MN
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1512
mi
from 91732
Fridley, MN
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2393
mi
from 91732
Whitehouse Station, NJ
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2393
mi
from 91732
Whitehouse Station, NJ
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
654
mi
from 91732
Albuquerque, NM
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
654
mi
from 91732
Albuquerque, NM
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2441
mi
from 91732
Bronx, NY
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2441
mi
from 91732
Bronx, NY
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2478
mi
from 91732
Stony Brook, NY
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2478
mi
from 91732
Stony Brook, NY
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2217
mi
from 91732
Raleigh, NC
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2217
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1967
mi
from 91732
Sylva, NC
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1967
mi
from 91732
Sylva, NC
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2122
mi
from 91732
Winston-Salem, NC
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2122
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2037
mi
from 91732
Akron, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2037
mi
from 91732
Akron, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1880
mi
from 91732
Cincinnati, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2036
mi
from 91732
Cleveland, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1965
mi
from 91732
Columbus, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1965
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1952
mi
from 91732
Hilliard, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1952
mi
from 91732
Hilliard, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1973
mi
from 91732
Pickerington, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1973
mi
from 91732
Pickerington, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1964
mi
from 91732
Westerville, OH
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1964
mi
from 91732
Westerville, OH
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
829
mi
from 91732
Portland, OR
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
829
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2103
mi
from 91732
Beaver, PA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2103
mi
from 91732
Beaver, PA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2116
mi
from 91732
Erie, PA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2116
mi
from 91732
Erie, PA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2121
mi
from 91732
Pittsburgh, PA
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
2000
mi
from 91732
Gray, TN
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2000
mi
from 91732
Gray, TN
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1994
mi
from 91732
Kingsport, TN
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1994
mi
from 91732
Kingsport, TN
Click here to add this to my saved trials
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated:  12/31/1969
1211
mi
from 91732
Austin, TX
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1211
mi
from 91732
Austin, TX
Click here to add this to my saved trials